[DOI] [Google Scholar] 48.Livadas S, Androulakis I, Angelopoulos N, Lytras A, Papagiannopoulos F, Kassi G
In the United States, the Food and Drug Administration (FDA) classified BPC-157 as Category 2 for compounding due to adverse immune system reactions, peptide-related impurities and insufficient safety information to determine whether it would cause harm when administered to humans
The relationship between DAT blockade and TE levels in the blood or the dose given followed a specific pattern
A 1012 week on-cycle at the descending frequencies works out to roughly: activation 28 daily doses, consolidation 20 doses (5/wk 4 wks), and 24 maintenance weeks 612 doses call it ~5460 doses for the whole cycle, or about two 30-dose vials
LZ: Formal analysis, Methodology, Investigation, Writing review & editing
I would hear about it forever